Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX5 | P09917 | 11/20 | 0.59 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.39 |
| ▸ | DHODH | Q02127 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 3/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.37 |
| ▸ | MAPT | P10636 | 3/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | HTR2B | P41595 | 2/20 | 0.34 |
| ▸ | HTR7 | P34969 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1919570 | 0.77 | ALOX5 (0.59) | ALOX5GAANPSR1DHODHMEN1 | |
| SCHEMBL3870286 | 0.77 | ALOX5 (0.59) | ALOX5GAANPSR1DHODHMEN1 | |
| SCHEMBL1867030 | 0.77 | ALOX5 (0.59) | ALOX5GAANPSR1DHODHMEN1 | |
| SCHEMBL339368 | 0.77 | ALOX5 (0.60) | ALOX5GAANPSR1DHODHMEN1 | |
| SCHEMBL5320399 | 0.77 | ALOX5 (0.59) | ALOX5GAANPSR1DHODHMEN1 | |
| SCHEMBL2724592 | 0.77 | ALOX5 (0.59) | ALOX5GAANPSR1DHODHMEN1 | |
| SCHEMBL1867028 | 0.77 | ALOX5 (0.59) | ALOX5GAANPSR1DHODHMEN1 | |
| SCHEMBL89676 | 0.77 | ALOX5 (0.59) | ALOX5GAANPSR1DHODHMEN1 | |
| SCHEMBL31191625 | 0.77 | ALOX5 (0.59) | ALOX5GAANPSR1DHODHMEN1 | |
| SCHEMBL31666385 | 0.77 | ALOX5 (0.59) | ALOX5GAANPSR1DHODHMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10654869-B2 | Bacterial topoisomerase I inhibitors with antibacterial activity | THE FLORIDA INTERNATIONAL UNIVERSITY BOARD OF TRUSTEES (US) | 2020-05-19 | — | — | US | disclosed |
| US-20190194224-A1 | BACTERIAL TOPOISOMERASE I INHIBITORS WITH ANTIBACTERIAL ACTIVITY | THE FLORIDA INTERNATIONAL UNIVERSITY BOARD OF TRUSTEES | 2019-06-27 | — | — | US | disclosed |
| US-10266550-B2 | Bacterial topoisomerase I inhibitors with antibacterial activity | THE FLORIDA INTERNATIONAL UNIVERSITY BOARD OF TRUSTEES (US) | 2019-04-23 | — | — | US | disclosed |
| US-20180079757-A1 | BACTERIAL TOPOISOMERASE I INHIBITORS WITH ANTIBACTERIAL ACTIVITY | THE FLORIDA INTERNATIONAL UNIVERSITY BOARD OF TRUSTEES | 2018-03-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180079757-A1 | BACTERIAL TOPOISOMERASE I INHIBITORS WITH ANTIBACTERIAL ACTIVITY | TOP1, TOP2A, TOP2B | ALOX5 2757/4885GAA 180/4885NPSR1 4839/4885 |
| US-10654869-B2 | Bacterial topoisomerase I inhibitors with antibacterial activity | TOP1, TOP2A, TOP2B | ALOX5 2757/4885GAA 180/4885NPSR1 4839/4885 |
| US-10266550-B2 | Bacterial topoisomerase I inhibitors with antibacterial activity | TOP1, TOP2A, TOP2B | ALOX5 2757/4885GAA 180/4885NPSR1 4839/4885 |
| US-20190194224-A1 | BACTERIAL TOPOISOMERASE I INHIBITORS WITH ANTIBACTERIAL ACTIVITY | TOP1, TOP2A, TOP2B | ALOX5 2861/4885GAA 174/4885NPSR1 4840/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.